Close
4

Seqens Seqens

X

Company profile for Biosight

  • Webinars & Exhibitions

PharmaCompass
About the Company
Biosight is a private Phase 2 clinical stage biotech company, developing innovative therapeutics for hematological malignancies and disorders. ​Biosight’s lead product, BST-236 (INN aspacytarabine), is an innovative proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of ac...
Biosight is a private Phase 2 clinical stage biotech company, developing innovative therapeutics for hematological malignancies and disorders. ​Biosight’s lead product, BST-236 (INN aspacytarabine), is an innovative proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML), following a successful and encouraging Phase 1/2a, which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard therapy.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
Biosight
Israel Flag
Country
Country
Israel
Address
Address
3 Hayarden St., Airport City​ P.O.B 1083 Lod 7019802
Telephone
Telephone
+972.3.6568669
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY